JANSSEN's RISPERDAL LONG-TERM PHASE IV EFFICACY STUDIES NEEDED, FDA SAYS IN DEC. 29 APPROVAL; AGENCY WARNS AGAINST SUPERIORITY CLAIMS TO OTHER ANTIPSYCHOTICS
Executive Summary
Janssen's Risperdal (risperidone) was approved Dec. 29 for the treatment of psychotic disorders with the company's assurance that it will conduct Phase IV long-term efficacy studies.